Meeting
2014 ASCO Annual Meeting
Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.
Authors
Erica L. Mayer
Dana-Farber Cancer Institute, Boston, MA
Erica L. Mayer , Adrienne Brana Gropper , Nadine M. Tung , Michaela Jane Higgins , Tiffany A. Traina , William Thomas Barry , Eric P. Winer , Harold J. Burstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT02040857
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS654)
DOI
10.1200/jco.2014.32.15_suppl.tps654
Abstract #
TPS654
Poster Bd #
117A
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2021 ASCO Annual Meeting
A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.
First Author: Oana Cristina Danciu
Poster
2021 ASCO Annual Meeting
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
First Author: Akshara Singareeka Raghavendra